{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-204493","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.597611+00:00","generated_at":"2026-06-12T04:51:45.312551+00:00","sec_items":["1.01","5.03","2.01","3.02","1.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ikena Oncology acquires Pionyr in all-stock deal, receives ~$43M net cash","bullets":["Ikena issued 1.8M common shares and 4.2M Series A convertible preferred shares at $7.15/share for all of Pionyr.","Pionyr contributed ~$43M net cash; Ikena to use funds to accelerate IK-930 and IK-595 clinical programs.","Pionyr shareholders (including Gilead Sciences) hold ~12% of Ikena post-deal; management and board unchanged.","CVRs grant Pionyr holders 50% of net proceeds from any monetization of Pionyr legacy assets within two years.","Ikena expects initial IK-930 clinical data in 2023 and IK-595 IND filing later in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-204493","json":"https://secwatch.observer/filing/0001193125-23-204493.json","markdown":"https://secwatch.observer/filing/0001193125-23-204493.md","text":"https://secwatch.observer/filing/0001193125-23-204493.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/0001193125-23-204493-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/d469204d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:51:45.312551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4fb79caccab05db6e85c56a3aac84cc256df6815","claim":"ImageneBio, Inc.: Filed Certificate of Designation establishing Series A Non-Voting Convertible Preferred Stock (effective 2023-08-04).","evidence_excerpt":"On August 4, 2023, Ikena filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware (the “ Certificate of Designation ”) in connection with the Merger referenced in Item 1.01 above.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/0001193125-23-204493-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-08-04"}],"fact_type":"governance_change"},{"claim_id":"8a8fac9acd4746e9f1d0cc46556528de7c9e442f","claim":"ImageneBio, Inc. completed an acquisition involving Pionyr Immunotherapeutics, Inc. (closed 2023-08-04).","evidence_excerpt":"On August 4, 2023, Ikena completed its business combination with Pionyr.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/0001193125-23-204493-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Pionyr Immunotherapeutics, Inc."},{"label":"Closing","value":"2023-08-04"}],"fact_type":"ma_transaction"},{"claim_id":"3e9833092ac433369525e382a83ff427cf2bf5e1","claim":"ImageneBio, Inc. entered into Support Agreements with certain stockholders of Ikena.","evidence_excerpt":"In connection with the execution of the Merger Agreement, Ikena and Pionyr entered into stockholder support agreements (the “ Support Agreements ”) with certain stockholders of Ikena.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/0001193125-23-204493-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"certain stockholders of Ikena"}],"fact_type":"material_agreement"},{"claim_id":"47ba5b791bc8bae58596cc0786243bb052dcefaa","claim":"ImageneBio, Inc. entered into Merger Agreement with Ikena Oncology, Inc. and Pionyr Immunotherapeutics, Inc..","evidence_excerpt":"Under the terms of the Merger Agreement, outstanding options to acquire Pionyr Common Stock (each, a “ Company Option ”) that had an exercise price greater than the Per Share Cash Consideration (as defined in the Merger Agreement) were cancelled","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/0001193125-23-204493-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Ikena Oncology, Inc. and Pionyr Immunotherapeutics, Inc."}],"fact_type":"material_agreement"},{"claim_id":"51444894bc0d7b521dbdff7f69ba29dca9c122b7","claim":"ImageneBio, Inc. entered into CVR Agreement with Ikena and the Rights Agent.","evidence_excerpt":"In connection with the Merger, Ikena and the Rights Agent (as defined therein) entered into a contingent value rights agreement (the “ CVR Agreement ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/0001193125-23-204493-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Ikena and the Rights Agent"}],"fact_type":"material_agreement"},{"claim_id":"5de684011d5e73911d47b3343b9e16041aeb1457","claim":"ImageneBio, Inc. entered into Lock-up Agreements with certain Pionyr securityholders.","evidence_excerpt":"Concurrently and in connection with the execution of the Merger Agreement, certain Pionyr securityholders as of immediately prior to the Merger entered into lock-up agreements with Ikena and Pionyr","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523204493/0001193125-23-204493-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"certain Pionyr securityholders"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}